JP2021507924A5 - - Google Patents

Download PDF

Info

Publication number
JP2021507924A5
JP2021507924A5 JP2020535008A JP2020535008A JP2021507924A5 JP 2021507924 A5 JP2021507924 A5 JP 2021507924A5 JP 2020535008 A JP2020535008 A JP 2020535008A JP 2020535008 A JP2020535008 A JP 2020535008A JP 2021507924 A5 JP2021507924 A5 JP 2021507924A5
Authority
JP
Japan
Prior art keywords
dpb1
hla
item
cancer
immunotherapeutic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020535008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021507924A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/067380 external-priority patent/WO2019126799A1/en
Publication of JP2021507924A publication Critical patent/JP2021507924A/ja
Publication of JP2021507924A5 publication Critical patent/JP2021507924A5/ja
Priority to JP2024031183A priority Critical patent/JP2024051157A/ja
Pending legal-status Critical Current

Links

JP2020535008A 2017-12-22 2018-12-21 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法 Pending JP2021507924A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024031183A JP2024051157A (ja) 2017-12-22 2024-03-01 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609589P 2017-12-22 2017-12-22
US62/609,589 2017-12-22
PCT/US2018/067380 WO2019126799A1 (en) 2017-12-22 2018-12-21 Major histocompatibility complex (mhc) compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024031183A Division JP2024051157A (ja) 2017-12-22 2024-03-01 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2021507924A JP2021507924A (ja) 2021-02-25
JP2021507924A5 true JP2021507924A5 (https=) 2021-12-16

Family

ID=66993888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020535008A Pending JP2021507924A (ja) 2017-12-22 2018-12-21 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法
JP2024031183A Pending JP2024051157A (ja) 2017-12-22 2024-03-01 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024031183A Pending JP2024051157A (ja) 2017-12-22 2024-03-01 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法

Country Status (4)

Country Link
US (1) US20210060126A1 (https=)
EP (1) EP3727467A4 (https=)
JP (2) JP2021507924A (https=)
WO (1) WO2019126799A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
JP7555822B2 (ja) 2018-04-19 2024-09-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア ゲノム編集のための組成物および方法
WO2021063340A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途
WO2022192701A1 (en) * 2021-03-12 2022-09-15 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074904B2 (en) * 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
EP0995798A1 (en) * 1998-10-24 2000-04-26 Novimmune Sa Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2002068614A2 (en) * 2001-02-26 2002-09-06 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
GB0109114D0 (en) * 2001-04-11 2001-05-30 King S College London Stimulation of the immune system
WO2006081629A1 (en) * 2005-02-04 2006-08-10 Stem Cell Australia Pty Ltd Adenoviral vectors comprising a nucleic acid encoding a mhc class i molecule and the use of such vectors in cancer therapy.
US8491913B2 (en) * 2009-03-07 2013-07-23 Oregon Health & Science University Compositions and methods using recombinant MHC molecules for the treatment of stroke
WO2012145384A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
US20160186208A1 (en) * 2013-04-16 2016-06-30 Whitehead Institute For Biomedical Research Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
CN106459990B (zh) * 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
CN108026154B (zh) * 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
EP3402901A1 (en) * 2016-01-11 2018-11-21 Dixon, Janette Methods for determining tumour phenotypes
EP3419657A4 (en) * 2016-02-25 2019-11-06 Briacell Therapeutics Corp. CELLULAR CANCER VACCINES AND METHOD FOR SELECTION THEREOF
US20170321285A1 (en) * 2016-05-03 2017-11-09 The Texas A&M University System Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
EP3452101A2 (en) * 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein

Similar Documents

Publication Publication Date Title
Shirley et al. Type I IFN sensing by cDCs and CD4+ T cell help are both requisite for cross-priming of AAV capsid-specific CD8+ T cells
Xiao et al. CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
JP2021507924A5 (https=)
Sun et al. MHC class II restricted neoantigen: a promising target in tumor immunotherapy
US20210379168A1 (en) Methods for profiling the t-cel- receptor repertoire
CN108025048B (zh) 共有的新抗原
US10550430B2 (en) Method and kit for determining whether a subject shows an immune response
CN112368386A (zh) 共有抗原
CN119656304A (zh) 使用肿瘤微环境的特征的嵌合受体t细胞治疗
JP2017531687A (ja) 養子細胞免疫療法の有効性を増強させるための組成物および方法
CN112912507A (zh) 甲病毒新抗原载体和干扰素抑制剂
Annels et al. Oncolytic reovirus-mediated recruitment of early innate immune responses reverses immunotherapy resistance in prostate tumors
CN110545810A (zh) 新抗原的病毒递送
Kottke et al. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
WO2019200316A1 (en) Adoptive cellular therapy
Cousin et al. Persistence of integrase-deficient lentiviral vectors correlates with the induction of STING-independent CD8+ T cell responses
US20220125951A1 (en) Microenvironment sensors to regulate engineered gene expression
Zheng et al. Epigenetically suppressed tumor cell intrinsic STING promotes tumor immune escape
US20260071282A1 (en) Method of improving prediction of response for cancer patients treated with immunotherapy
JP2024051157A5 (https=)
Odegard et al. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy
Tenesaca et al. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors
Xu et al. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
US20220227883A1 (en) Immunotherapy constructs targeting kras antigens
Wang et al. Cancer immunology: immune escape of tumors—expression and regulation of HLA class I molecules and its role in immunotherapies